Zoetis Inc. (NYSE:ZTS) Shares Purchased by Bogart Wealth LLC

Bogart Wealth LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 9,510.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,986 shares of the company’s stock after buying an additional 24,726 shares during the quarter. Bogart Wealth LLC’s holdings in Zoetis were worth $4,931,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. River Street Advisors LLC raised its position in Zoetis by 3.4% during the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after buying an additional 58 shares during the last quarter. Perigon Wealth Management LLC raised its position in Zoetis by 0.3% during the 4th quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after buying an additional 59 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Zoetis by 5.0% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after buying an additional 61 shares during the last quarter. Ellevest Inc. raised its position in Zoetis by 2.4% during the 3rd quarter. Ellevest Inc. now owns 2,790 shares of the company’s stock worth $485,000 after buying an additional 66 shares during the last quarter. Finally, Atria Wealth Solutions Inc. raised its position in Zoetis by 0.4% during the 3rd quarter. Atria Wealth Solutions Inc. now owns 15,975 shares of the company’s stock worth $2,779,000 after buying an additional 70 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Zoetis stock traded down $3.53 during trading on Wednesday, reaching $164.92. The company had a trading volume of 4,669,191 shares, compared to its average volume of 3,195,939. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The firm’s 50-day simple moving average is $167.64 and its 200 day simple moving average is $178.93. The firm has a market capitalization of $75.25 billion, a PE ratio of 31.78, a price-to-earnings-growth ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter in the previous year, the company posted $1.31 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. The Goldman Sachs Group cut their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $211.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 in the last 90 days. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.